
Teva’s EpiPen generic retails for same price as Mylan’s own
pharmafile | November 28, 2018 | News story | Research and Development, Sales and Marketing | Mylan, Teva, epipen, pharma
Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at $300 wholesale for a pack of two, it comes in at exactly the same point as Mylan’s own long-anticipated generic version.
The announcement means that patients have two alternative options for the therapy, which both come in at less than half the cost of the branded product.
The recent shortage of EpiPens, which Mylan blames on manufacturing issues at a plant run by Pfizer, has compounded the need for cheaper, generic versions. With the launch of the Teva’s product, it is now available in the US, albeit with limited supply; the company appeared unable to confirm how many it had released into the market, noting that the product is complex in nature and manufacturing only began in August following its FDA approval.
According to Teva, additional supply is inbound next year, as well as a generic version of Mylan’s EpiPen Jr, which carries a lower dose.
Matt Fellows
Related Content

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






